Study S003370

A Single-center, Randomized, Open, Three-period, Three-sequence Crossover Clinical Study to Compare the Bioavailability and Safety of a Single Subcutaneous Injection of HR17031 in Healthy Subjects at Different Sites

ClinicalTrials.gov record

Registration

Registration: NCT06086912
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: NONE
Status: COMPLETED
Enrollment: 24
Start: 2023-11-07
Primary completion: 2023-12-12
Lead sponsor: Jiangsu HengRui Medicine Co., Ltd.
Conditions: Type 2 Diabetes
Interventions: DRUG:HR17031
Results posted: FALSE
Individual participant data sharing: UNDECIDED

Registered primary outcomes

After a single subcutaneous injection of HR17031, the PK parameters of plasma Noiiglutide and serum INS068: Area Under the Concentration versus time curve (AUC0-t) [Start of treatment up to Day 26]
After a single subcutaneous injection of HR17031, the PK parameters of plasma Noiiglutide and serum INS068: Area Under the Concentration versus time curve (AUC0-∞) [Start of treatment up to Day 26]
After a single subcutaneous injection of HR17031, the PK parameters of plasma Noiiglutide and serum INS068: Maximum Concentration (Cmax) [Start of treatment up to Day 26]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.